683 Capital Management LLC Buys New Stake in Atyr PHARMA INC (NASDAQ:ATYR)

683 Capital Management LLC acquired a new stake in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 248,000 shares of the company's stock, valued at approximately $898,000. 683 Capital Management LLC owned approximately 0.30% of Atyr PHARMA at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of ATYR. Alterna Wealth Management Inc. purchased a new stake in shares of Atyr PHARMA during the fourth quarter worth approximately $36,000. Victory Capital Management Inc. acquired a new position in Atyr PHARMA during the 4th quarter worth approximately $37,000. Raymond James Financial Inc. purchased a new stake in shares of Atyr PHARMA in the 4th quarter valued at approximately $39,000. JPMorgan Chase & Co. raised its stake in Atyr PHARMA by 52.0% in the third quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company's stock valued at $55,000 after buying an additional 10,754 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Atyr PHARMA during the 4th quarter worth about $40,000. 61.72% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have issued reports on ATYR. Leerink Partners assumed coverage on shares of Atyr PHARMA in a research note on Tuesday, February 18th. They issued an "outperform" rating and a $16.00 price objective for the company. HC Wainwright reissued a "buy" rating and issued a $35.00 price objective on shares of Atyr PHARMA in a research note on Friday, March 14th. Finally, Leerink Partnrs raised Atyr PHARMA to a "strong-buy" rating in a research note on Tuesday, February 18th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $18.60.

Atyr PHARMA Price Performance

Shares of NASDAQ ATYR traded down $0.02 during trading on Wednesday, reaching $3.22. The company had a trading volume of 661,779 shares, compared to its average volume of 904,590. The stock has a market capitalization of $285.68 million, a PE ratio of -3.42 and a beta of 0.79. The stock has a 50-day moving average price of $3.27 and a two-hundred day moving average price of $3.40. Atyr PHARMA INC has a twelve month low of $1.42 and a twelve month high of $4.66. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last released its earnings results on Thursday, March 13th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.05. As a group, sell-side analysts predict that Atyr PHARMA INC will post -0.91 earnings per share for the current year.

Atyr PHARMA Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.